$JKS

JinkoSolar to Report Second Quarter 2026 Results on August 26, 2026

JinkoSolar Holding Co., Ltd. (NYSE: JKS) said it will release unaudited Q2 2026 results for the quarter ended June 30, 2026 before the U.S. market open on Aug. 26, 2026. Management will host an earnings call that day at 8:30 a.m. ET, with a webcast and telephone replay available afterward.

Original reporting
Published Aug 14, 2026, 12:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 1:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$JKS
Neutral
medium confidence
Mentioned
$JKS
Relevance
4/10
alphai data visualization · based on prnewswire.com
Decision brief

The 30-second read

$JKSNeutralMed
01

Why it matters

The main tradable element is the fixed earnings timing, which can affect near-term hedging, implied volatility, and pre-earnings positioning.

02

Market read

This is a calendar-setting earnings announcement with no new financial figures, guidance, or operational updates.

03

What to watch

Implied volatility and positioning can still shift if the market expects material changes in margins, demand, or pricing, but those expectations are not addressed in this PR.

Relevance 4/10Novelty 3/10Timing: earnings release scheduled before the U.S. open on Aug. 26, 2026

Background

JinkoSolar scheduled its unaudited Q2 2026 results release and earnings conference call for Aug. 26, 2026.

Company-level read

Ticker impact

$JKSNeutralMedium confidence
Context

JinkoSolar announced it will release unaudited Q2 2026 results before the U.S. open on Aug. 26, 2026, with a call at 8:30 a.m. ET.

Expected impact

Likely increased options and volume activity ahead of Aug. 26; direction depends on the Q2 print and guidance not provided here.

Evidence & confidence

The article discloses only the scheduled reporting and call logistics, not results, guidance, or new fundamentals.

Market effects

Adds another scheduled earnings catalyst for the solar/clean-energy names, but provides no sector datapoints.

Limited, as the disclosure is company-specific and does not cite China policy or regional demand changes.

Low, since it is a standard earnings timing announcement without new guidance or macro/regulatory triggers.

Counterpoint

Because the release date is already a known type of catalyst, traders may treat it as largely priced-in until the actual results and guidance are released.

Key entities

  • JinkoSolar Holding Co., Ltd.

    NYSE-listed solar company scheduling Q2 2026 results release and an earnings call on Aug. 26, 2026.

  • NYSE: JKS

    The company’s listed equity referenced in the announcement.

Related articles

$JKSMed

JinkoSolar, LONGi Green and Canadian Solar focus on module efficiency and quality ahead of new mandatory Chinese PV standards

China’s energy efficiency PV standard, issued by multiple ministries, takes effect 1 Jan 2027 and sets tiered module conversion thresholds by cell type. Modules below Grade 3 will be barred from production and sales. JinkoSolar, LONGi Green and Canadian Solar discussed impacts on procurement criteria and capacity, plus storage expansion plans.

$JKSMed

JinkoSolar Hits 34.82% Tandem Solar Efficiency: TOPCon Platform Clears Silicon Ceiling

JinkoSolar said its N-type TOPCon perovskite-silicon tandem cell reached 34.82% certified power conversion efficiency on June 19, according to certification by the Shanghai Institute of Microsystem and Information Technology (Chinese Academy of Sciences). The result tops its prior 34.76% tandem record and marks its 33rd efficiency/module output world record. Investors will watch whether the TOPCon-compatible platform can scale while maintaining stability.

$JKSMed

JinkoSolar Announces Cash Dividend

JinkoSolar Holding Co. (NYSE: JKS) announced a cash dividend of $0.375 per ordinary share (US$1.50 per ADS). Shareholders of record at June 22, 2026 will receive it, with payment expected around July 9, 2026. The company expects to distribute about $78.5 million in total.

$GILDHighAI 8/10

Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?

Gilead Sciences (GILD) reported Q2 2026 with double-digit growth in commercial portfolio sales, but posted a significant loss due to $11.2B in R&D expenses from acquisitions. HIV sales rose 12% to $5.7B, while non-HIV areas like liver disease and cancer treatments also showed growth. The company raised its 2026 sales guidance and made strategic acquisitions, but faces risks from clinical development and financial obligations.

$ABBVMedAI 8/10

AbbVie’s Humira Replacement Strategy Is Working, But Could Growth Be Too Concentrated?

AbbVie (NYSE:ABBV) reported Q2 2026 revenue of $16.99B, up 10.2%, driven by immunology and neuroscience. Skyrizi and Rinvoq revenues grew 24.4% and 24.5% respectively, offsetting Humira's 35.9% decline. However, concentration risk exists as these two products made up 47% of revenue. Oncology and aesthetics showed weaker performance, with oncology revenue down 1.5%. Adjusted EPS rose 22.9% to $3.65.